4/A: Revolution Medicines Director Lorence H. Kim Amends Form 4 Filing to Correctly Report Stock Option and RSU Awards

Lorence H. Kim, a director at Revolution Medicines, filed an amended Form 4 to correct previously reported amounts for restricted stock units (RSUs) and stock option awards granted on June 20, 2024.

Summary

• Lorence H. Kim, a director of Revolution Medicines, filed an amendment to a previous Form 4 filing.
• The amendment corrects inaccuracies in the reported amounts of restricted stock units (RSUs) and stock option awards granted to Kim on June 20, 2024.
• The corrected filing shows Kim acquired 4,248 shares of common stock through RSUs and was granted a stock option to purchase 15,955 shares.
• The stock option has an exercise price of $37.54 and vests on the earlier of the first anniversary of the grant date (June 20, 2024) or immediately before the company's next annual meeting, contingent on continued service.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing. The sentiment is neutral as it simply corrects a previous error in reporting.

Industry Context

Form 4 filings are standard disclosures required by the SEC for company insiders, providing transparency into their transactions in the company's securities. Amendments are common when errors are identified in the original filings.

Stakeholder Impact

• The corrected filing ensures accurate information is available to shareholders regarding insider ownership and potential dilution.

Key Dates